Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 4
1989 10
1990 7
1991 12
1992 19
1993 25
1994 14
1995 23
1996 15
1997 16
1998 13
1999 18
2000 29
2001 26
2002 36
2003 36
2004 35
2005 45
2006 34
2007 26
2008 45
2009 48
2010 54
2011 49
2012 68
2013 54
2014 37
2015 37
2016 38
2017 21
2018 37
2019 34
2020 22
Text availability
Article attribute
Article type
Publication date

Search Results

910 results
Results by year
Filters applied: . Clear all
Page 1
Post-transplant lymphoproliferative disorders.
Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Dharnidharka VR, et al. Nat Rev Dis Primers. 2016 Jan 28;2:15088. doi: 10.1038/nrdp.2015.88. Nat Rev Dis Primers. 2016. PMID: 27189056 Review.
Recipient EBV seronegativity and the intensity of immunosuppression are among key risk factors. Symptoms and signs depend on the localization of the lymphoid masses. ...Pre-emptive intervention based on monitoring EBV levels in blood has emerged as the preferred str …
Recipient EBV seronegativity and the intensity of immunosuppression are among key risk factors. Symptoms and signs depend on the loca …
Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Allen UD, Preiksaitis JK; AST Infectious Diseases Community of Practice. Allen UD, et al. Clin Transplant. 2019 Sep;33(9):e13652. doi: 10.1111/ctr.13652. Epub 2019 Jul 23. Clin Transplant. 2019. PMID: 31230381
Pre-transplant EBV-seronegativity and primary EBV infection, often from donor-transmitted infection, are an important risk factors for EBV syndromes and early EBV + PTLD. ...Treatment of CD20(+) PTLD with the response-dependent sequential use of …
Pre-transplant EBV-seronegativity and primary EBV infection, often from donor-transmitted infection, are an important risk fac …
Epstein-Barr virus infection and posttransplant lymphoproliferative disorder.
Green M, Michaels MG. Green M, et al. Am J Transplant. 2013 Feb;13 Suppl 3:41-54; quiz 54. doi: 10.1111/ajt.12004. Am J Transplant. 2013. PMID: 23347213 Free article. Review.
Other therapies, including the rituximab (anti-CD20 monoclonal antibody) and traditional chemotherapy, are also useful in the treatment of established PTLD. The future development of standards for management based on EBV viral load and routine monitoring of EBV
Other therapies, including the rituximab (anti-CD20 monoclonal antibody) and traditional chemotherapy, are also useful in the treatme …
Prognostic significance of CD20 expression and Epstein-Barr virus (EBV) association in classical Hodgkin lymphoma in Japan: a clinicopathologic study.
Elsayed AA, Asano N, Ohshima K, Izutsu K, Kinoshita T, Nakamura S. Elsayed AA, et al. Pathol Int. 2014 Jul;64(7):336-45. doi: 10.1111/pin.12175. Pathol Int. 2014. PMID: 25047504
To investigate the clinicopathological significance of CD20 expression and Epstein-Barr virus (EBV) association in Hodgkin and Reed-Sterberg cells of classical Hodgkin lymphoma (CHL), CD20 expression and EBV positivity (by EBER in situ hybridization) w …
To investigate the clinicopathological significance of CD20 expression and Epstein-Barr virus (EBV) association in Hodgkin and …
De Novo Unclassifiable CD20-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic and Therapeutic Challenge.
AbdullGaffar B, Seliem RM. AbdullGaffar B, et al. Int J Surg Pathol. 2018 May;26(3):266-270. doi: 10.1177/1066896917735170. Epub 2017 Oct 5. Int J Surg Pathol. 2018. PMID: 28982264
CD20-negative diffuse large B-cell lymphomas (DLBCLs) constitute a rare and heterogeneous group of aggressive lymphomas. Known well-documented variants include plasmablastic lymphomas, primary effusion lymphomas, anaplastic kinase-positive large B-cell lymphomas, and large
CD20-negative diffuse large B-cell lymphomas (DLBCLs) constitute a rare and heterogeneous group of aggressive lymphomas. Known well-d
Lymphoproliferative disorders with concurrent HHV8 and EBV infection: beyond primary effusion lymphoma and germinotropic lymphoproliferative disorder.
Wang W, Kanagal-Shamanna R, Medeiros LJ. Wang W, et al. Histopathology. 2018 Apr;72(5):855-861. doi: 10.1111/his.13428. Epub 2018 Jan 3. Histopathology. 2018. PMID: 29105119
AIMS: Lymphoproliferative disorders (LPD) characterised by human herpesvirus 8 (HHV8) and Epstein-Barr virus (EBV) infection are rare and two entities are included in the World Health Organisation classification: primary effusion lymphoma (PEL) and germinotro …
AIMS: Lymphoproliferative disorders (LPD) characterised by human herpesvirus 8 (HHV8) and Epstein-Barr virus (EBV) infe …
[Clinical features and prognosis of CD20-positive classical Hodgkin lymphoma].
Qin Y, Kang SY, He XH, Zhou SY, Liu P, Yang JL, Zhang CG, Yang S, Gui L, Shi YK. Qin Y, et al. Zhonghua Yi Xue Za Zhi. 2016 Jul 26;96(28):2224-8. doi: 10.3760/cma.j.issn.0376-2491.2016.28.005. Zhonghua Yi Xue Za Zhi. 2016. PMID: 27480653 Chinese.
Patients positive in both CD20 expression and EBV-encoded small RNAs (EBER) showed low PFS. CONCLUSIONS: CD20 expression in R-S cells in CHL may be closed related with EBV infection. EBV infection is associated with unfavorable prognosis. The ef …
Patients positive in both CD20 expression and EBV-encoded small RNAs (EBER) showed low PFS. CONCLUSIONS: CD20 expressio …
Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.
Chellapandian D, Das R, Zelley K, Wiener SJ, Zhao H, Teachey DT, Nichols KE; EBV-HLH Rituximab Study Group. Chellapandian D, et al. Br J Haematol. 2013 Aug;162(3):376-82. doi: 10.1111/bjh.12386. Epub 2013 May 21. Br J Haematol. 2013. PMID: 23692048 Free PMC article.
Haemophagocytic lymphohistiocytosis (HLH) is a life threatening complication of Epstein-Barr virus (EBV) infection. The anti-CD20 antibody rituximab depletes B cells, leading to improved outcomes for patients with EBV-associated B-lymphoproliferative disorder …
Haemophagocytic lymphohistiocytosis (HLH) is a life threatening complication of Epstein-Barr virus (EBV) infection. The anti-CD20
New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.
Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Caroline D, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C. Gamonet C, et al. Exp Hematol Oncol. 2016 Mar 1;5:7. doi: 10.1186/s40164-016-0036-3. eCollection 2015. Exp Hematol Oncol. 2016. PMID: 26937306 Free PMC article.
Moreover, Epstein-Barr virus (EBV) transformation modified the CD20 splicing profile and mainly increased the D393-CD20 variant transcripts. ...CONCLUSION: The involvement of these newly discovered alternative CD20 transcript variants in EBV tra …
Moreover, Epstein-Barr virus (EBV) transformation modified the CD20 splicing profile and mainly increased the D393-CD20
EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT.
Ocheni S, Kroeger N, Zabelina T, Sobottka I, Ayuk F, Wolschke C, Muth A, Lellek H, Petersen L, Erttmann R, Kabisch H, Zander AR, Bacher U. Ocheni S, et al. Bone Marrow Transplant. 2008 Aug;42(3):181-6. doi: 10.1038/bmt.2008.150. Epub 2008 Jun 2. Bone Marrow Transplant. 2008. PMID: 18516079
Specifically, the incidence of EBV-PTLD was 1.3%, whereas that of EBV reactivation was 1.8%. Median age was 46.0 and 11.0 years in the adult and pediatric patients, respectively. ...Variable treatment regimens were applied including in most cases an anti-CD20
Specifically, the incidence of EBV-PTLD was 1.3%, whereas that of EBV reactivation was 1.8%. Median age was 46.0 and 11.0 year …
910 results
Jump to page
Feedback